



Suppl. Figure S1: Hemizygosity of *Birc5* does not alter proliferation, apoptosis and angiogenesis of NB. Tumors were formalin-fixed, paraffin-embedded, stained and analyzed. Scale bars equal 100 µm and 50µm (insert). Statistical analysis was performed using the unpaired two-tailed t-test. n.s., not significant. **A) Hemizygosity of *Birc5* does not alter tumor tissue.** Shown is one representative picture of H&E stained tumors per genotype. **B) Proliferation of tumor cells is not decreased by hemizygosity of *Birc5*.** Representative Ki67 stains are shown in the left panel, respectively. Ki67-positive cells were counted as % of nucleated cells in 3-4 representative visual fields (x40) per tumor and are depicted as means and standard deviations (right panel). **C) Hemizygosity of *Birc5* does not increase apoptosis rate in the tumors.** Representative active caspase 3 stains are shown in the left panel, respectively. Active caspase 3-positive cells were counted as % of nucleated cells in 3-4 representative visual fields (x40) per tumor and are depicted as means and standard deviations (right panel). **D) Hemizygosity of *Birc5* does not attenuate angiogenesis in the tumors.** Representative CD31 stains are shown in the left panel, respectively. Scale bars equal 100 µm. CD31-positive vessels were counted in 4-5 representative visual fields (x20) per tumor and are depicted as means and standard deviations (right panel).